Clinical Trial Update: GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.

View source ↗

Summary

The GEMCAD-REVEAL study examines whether circulating tumor DNA can predict relapse in patients with locally advanced rectal cancer. The trial is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Snippet

Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo | Conditions: Patients With Locally Advanced Rectal Cancer | Status: ACTIVE_NOT_RECRUITING